Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 23 Show results per page	View Search Criteria \| Help With Results


1.		A Study of Tanespimycin (KOS-953) in Patients With Relapsed-Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				CA200-003 KAG-302, NCT00514371

Last Modified: 3/20/2007 First Published: 6/23/2004


2.		Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Any age				NCI				MSKCC-04056 NCI-6480, 6480, NCT00087386

Last Modified: 10/26/2007 First Published: 9/25/2004


3.		Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Metastatic Papillary or Clear Cell Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MSKCC-04082 6479, NCI-6479, NCT00093405

Last Modified: 8/23/2008 First Published: 10/25/2004


4.		Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Women With Refractory Locally Advanced or Metastatic Primary Adenocarcinoma of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				WSU-C-2803 6552, NCI-6552, NCT00096109

Last Modified: 4/2/2008 First Published: 2/18/2005


5.		Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Metastatic Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				CRUK-PH2/049 6500, NCI-6500, NCT00104897

Last Modified: 7/31/2006 First Published: 6/25/2005


6.		Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Hormone-Refractory Metastatic Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MAYO-MC0453 NCI-6651, 6651, NCT00118092

Last Modified: 10/10/2008 First Published: 8/12/2005


7.		Phase II Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Systemic Mastocytosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-06-C-0076 6454, NCI-6454, NCI-P6175, NCT00132015

Last Modified: 10/26/2007 First Published: 8/1/1999


8.		Phase I Study of Geldanamycin Analogue (AAG) in Patients With Advanced Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 to 75				Other				CRC-PHASE-I-PH1/074 NCI-T99-0013, EU-99055, NCT00003969, T99-0013

Last Modified: 4/7/2005 First Published: 10/1/1999


9.		Phase I Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Refractory or Advanced Solid Tumors or Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				MSKCC-99037 NCI-T99-0035, UCLA-0206019, NCT00004065, T99-0035

Last Modified: 8/31/2005 First Published: 10/1/1999


10.		Phase I Study of 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Unresectable Solid Tumors or Relapsed Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				MAYO-990102 NCI-T99-0058, NCT00004075, T99-0058

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute